Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world brigatinib in ALK-positive unresectable locally advanced or metastatic NSCLC
ChiCTR2600127112Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Guangdong Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brigatinib in ALK-positive non-small cell lung cancer, sponsored by The Affiliated Hospital of Guangdong Medical University. Primary endpoint: 2-year progression-free survival rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
brigatinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on ChiCTR2600127112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127112.